ClinicalTrials.gov
Cure8 trial brief
Why This Matters
This trial aims to identify IL-23–responsive immune cell types in the gut that may drive postoperative Crohn’s recurrence and influence response to IL-23–targeted drugs, which could help explain why some patients benefit from IL-23 blockade.
Who Should Pay Attention
Clinicians and researchers interested in Crohn’s immunology and IL-23, patients with postoperative recurrence, and patients receiving biologic therapy.
Study Snapshot
Story typeClinical Reference
Evidence typeClinical trial
Enrollment40 participants
Study statusRecruiting
Source depthTrial registry record
What To Know
This is a registered, recruiting observational trial (planned N=40) focused on patients with endoscopic postoperative recurrence (Rutgeerts > i2a) undergoing standard-care biologic treatment. The primary work involves single-cell analysis of mucosal samples to measure changes in IL-23–responsive cell concentrations before and after ~12–16 weeks of treatment.
The study is not testing a new drug intervention; participants receive biologics as part of routine care and researchers observe immunologic changes. Results, if published later, could help explain which IL-23–responsive cells drive recurrence and why IL-23–targeting therapies work in some patients.
Practical note: The protocol excludes patients who received biologics between surgery and the first endoscopy and requires a second ileocolonoscopy for follow-up sampling.
Keep In Mind
Registered on ClinicalTrials.gov as an observational, recruiting study at Amsterdam UMC and Mount Sinai Toronto. It uses single-cell analysis of mucosal biopsies before and ~12–16 weeks after routine biologic therapy; it does not test investigational drugs and is exploratory with limited sample size.
Source Details
Review the original publication for the complete reporting, methods, and context.
Clinical trial
Evidence type derived from source or registry metadata.
PublicationClinicalTrials.gov
SponsorAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Trial IDNCT06006039
Study typeObservational
Enrollment40 participants
Indexed viaClinicalTrials.gov
Source typeTrial registry record
PublishedNov 4, 2026, 12:00 AM
Content availableTrial registry record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Immune Regulation in Ulcerative Colitis or Crohn s Disease
This NIH natural-history study is collecting clinical, immune, and genetic samples from people with Crohn’s disease and ulcerative colitis to better understand immune pathways and molecular causes of IBD. Those findings...
Intertriginous/Periorificial Dermatoses in Patients With IBD on Anti-TNFα: Relative Abundance of Staphylococcus Aureus Within the Lesion Microbiota and Clinical Correlation (micSPIDER).
People with IBD who are treated with anti‑TNFα drugs commonly develop inflammatory or infectious skin problems. This study aims to clarify whether Staphylococcus aureus is more abundant in those lesions and whether its...
Decoding the Clinical Impact of Host and Microbial Intestinal Proteomic Landscape in Crohn's Disease
Researchers are studying how proteins from both the host and microbes in the gut relate to Crohn’s disease features. Findings could point to new noninvasive biomarkers or therapeutic strategies to correct dysbiosis,...